Keywords: Aurobindo, Cephalosporin facility, FDA ban, Pfizer supplie, Financial loss

India’s Aurobindo to lose $2 million a month due to US FDA ban alert

Article | 25 February 2011

Print This

Indian drugmaker Aurobindo Pharma (ARBN: BO), which has suffered a setback in exports to the USA after the Food and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in